Clinical trial
Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in…
NCT04263480 · Christian Buske, Other · Active, not recruiting
Key facts
| NCT number | NCT04263480 |
|---|---|
| Title | Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia |
| Official title | Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib Alone in Waldenström's Macroglobulinemia (CZAR-1) |
| Acronym | CZAR-1 |
| Lead sponsor | Christian Buske, Other |
| Collaborators | Amgen Industry Janssen, LP |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Waldenstrom Macroglobulinemia |
| Intervention type | Drug |
| Interventions | Carfilzomib + Ibrutinib, Ibrutinib |
| Enrollment | 99 |
| Start date | Aug 18, 2021 |
| Primary completion | Aug 1, 2028 |
| Completion | Aug 1, 2028 |
| First posted | Feb 10, 2020 |
| Last update posted | Apr 4, 2025 |
| Countries | Austria, Germany, Greece |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: